H.C. Wainwright analyst Joseph Pantginis initiated coverage of CalciMedica with a Buy rating and $20 price target. CalciMedica is focusing on developing first-in-class therapies for inflammatory diseases with high unmet need, the analyst tells investors in a research note. Backed by strong preclinical data and now translating to positive clinical data, the company’s lead asset Auxora is being developed for several acute inflammatory indications, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CALC: